Implementación de un Programa de Atención Farmacéutica en pacientes con Diabetes Mellitus Tipo 2 atendidos en el Hospital Básico INGINOST

Abstract

The main objective of this research study was to implement a Pharmaceutical Care program for patients with Diabetes Mellitus Type 2, treated at the Hospital Básico INGINOST, from November 2021 – March 2022. For which a retrospective observational study was carried out, in which through a descriptive analysis a database was collected from the clinical records of the patients. Who offered the Pharmaceutical Care service. The medical records were checked, and a total of 25 patients who met the criteria for the established inclusion were checked during the period November 2021 – March 2022; of which 28% corresponded to young adults and 72% to older adults, with the female sex being the most prevalent with 56%. In the health center, the first medical choice that was used was Metformin at 80%, followed by Glibenclamide used at 12%, in case of Metformin was rejected, was not tolerated by the patients or it was not improving their clinic situation. During the care period, it was detected that 20% of the patients suffered from a Drug-related problem. 8% of patients suffered from a health problem consequence of not receiving the medication they need (Drug-related problem 1), and the other 12% of patients suffered from a health problem as a result of negative clinical outcomes (Drug-Related Problem 3). The design of a pharmaceutical care model was received by the staff of the health center, allowing the detection of Drug-Related Problems, and improving the quality of life for the patients. This is why its prompt inclusion is suggested as a reference for medical and pharmaceutical staff in their daily activity.